OUTCOMES OF NEOADJUVANT CHEMOTHERAPY FOR STAGE II–III TRIPLE-NEGATIVE BREAST CANCER AT NGHE AN ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the treatment outcomes of neoadjuvant chemotherapy in patients with stage II–III triple-negative breast cancer (TNBC) treated at Nghe An Oncology Hospital.
Methods: A descriptive study combining retrospective and prospective data was conducted on 37 patients with stage II–III TNBC who received neoadjuvant chemotherapy at the Department of Medical Oncology 4, Nghe An Oncology Hospital, between March 2023 and April 2026. Treatment response was assessed based on clinical response and total pathological complete response (tpCR).
Results: The mean age of the patients was 53.1 years, with the highest proportion (62.2%) in the 40–60-year age group. Stage II and stage III disease accounted for 70.3% and 29.7% of cases, respectively. The total pathological complete response (tpCR) rate was 43.2%. A statistically significant association was observed between clinical response and tpCR (p < 0.001). However, no significant associations were found between tpCR and other clinicopathological factors, including age, menopausal status, tumor stage, nodal stage, histological subtype, histological grade, Ki-67 proliferation index, or chemotherapy regimen (all p > 0.05). All chemotherapy regimens were well tolerated, and no patient discontinued treatment because of treatment-related toxicity.
Conclusion: Neoadjuvant chemotherapy achieved a relatively high total pathological complete response rate in patients with stage II–III triple-negative breast cancer. Clinical response was a significant predictor of tpCR, whereas baseline clinicopathological characteristics were not associated with pathological complete response.
Article Details
Keywords
triple-negative breast cancer; neoadjuvant chemotherapy; total pathological complete response; tpCR.
References
2. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book. Accessed July 17, 2026. https://ascopubs.org/doi/10.1200/EDBK_159135
3. Phùng Thị H. Đặc điểm lâm sàng, mô bệnh học bệnh nhân ung thư vú có bộ ba âm tính ER(-), PR(-), HER2(-) giai đoạn 2005-2007 tại Bệnh viện K.
4. LÊ THANH ĐỨC. Nghiên cứu hiệu quả hóa trị bổ trợ trước phẫu thuật phác đồ AP trong ung thư vú giai đoạn III.
5. NGUYỄN THỊ THUỶ. Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn III.
6. Nguyễn Thị Minh Phương. Hiệu quả của phác đồ 4AC-4T liều dày trong điều trị tân bổ trợ ở bệnh nhân ung thư vú giai đoạn II, III. . J 108 - Clin Med Pharmacy Published online November 12, 2022.
7. G von M, A S, S L, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. The Lancet Oncology. 2014;15(7). doi:10.1016/S1470-2045(14)70160-3
8. Jh S, K B, Mc P, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(12). doi:10.1200/JCO.21.01506
9. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549
10. Metzger-Filho O, Collier K, Asad S, et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. npj Breast Cancer. 2021;7(1). doi:10.1038/s41523-021-00349-y
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
2. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book. Accessed July 17, 2026. https://ascopubs.org/doi/10.1200/EDBK_159135
3. Phùng Thị H. Đặc điểm lâm sàng, mô bệnh học bệnh nhân ung thư vú có bộ ba âm tính ER(-), PR(-), HER2(-) giai đoạn 2005-2007 tại Bệnh viện K.
4. LÊ THANH ĐỨC. Nghiên cứu hiệu quả hóa trị bổ trợ trước phẫu thuật phác đồ AP trong ung thư vú giai đoạn III.
5. NGUYỄN THỊ THUỶ. Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn III.
6. Nguyễn Thị Minh Phương. Hiệu quả của phác đồ 4AC-4T liều dày trong điều trị tân bổ trợ ở bệnh nhân ung thư vú giai đoạn II, III. . J 108 - Clin Med Pharmacy Published online November 12, 2022.
7. G von M, A S, S L, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. The Lancet Oncology. 2014;15(7). doi:10.1016/S1470-2045(14)70160-3
8. Jh S, K B, Mc P, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(12). doi:10.1200/JCO.21.01506
9. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549
10. Metzger-Filho O, Collier K, Asad S, et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. npj Breast Cancer. 2021;7(1). doi:10.1038/s41523-021-00349-y